GENEWIZ Acquires Beckman Coulter Gene Services
PTSM: Pharmaceutical Technology Sourcing and Management
GENEWIZ signs definitive agreement to acquire Beckman Coulter's gene services business.
Genomics service provider, GENEWIZ, has signed a definitive agreement to acquire the genomic services business of Beckman Coulter (GS), according to a Dec. 21, 2015 announcement.
GENEWIZ provides Sanger DNA sequencing, gene synthesis, next generation sequencing, molecular biology bioinformatics, and GLP/GLIA regulatory services. The gene sequencing division of Beckman Coulter provides Sanger and next generation gene sequencing services, with bioinformatics services.
This acquisition will support GENEWIZ’s global expansion strategy by leveraging GS’s 25-plus years of genomics capabilities. It will also aid the company’s international expansion by adding additional locations in the US, UK, China, and Japan.
The agreement was approved by the boards of directors of both companies and closed immediately.
Source: GENEWIZ
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
